✨ Your Portfolio is fetched and updated from zerodha.
Small Hospitals
Market Cap
₹27,415 Cr.
P/E
53.43

Key Ratios

Market cap
Market cap
27,415 Cr
PE
PE
53.43
Prom Holding
Prom Holding
53.79 %
ROE (%)
ROE (%)
22.42
ROCE (%)
ROCE (%)
29.05
Div Yield (%)
Div Yield (%)
0.73
Sales
Sales
2,529 Cr
OPM (%)
OPM (%)
28.38 %
Debt to Equity
Debt to Equity
-

About

Dr. Lal Pathlabs Limited is a leading provider of diagnostic and healthcare services in India.… Read more
Low
2294
52W Range
High
3654
  • Dr. Lal Pathlabs
  • Vijaya Diagnostic
  • Metropolis Health.
  • TJI Diagnostic Chains

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

35 %
(as of Mar 18)
Diagnostic Chains Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Distribution Channel

Operational Metrics

    Select a Metric
    • Number of Diagnostic Centres (.)
    • Realization/Patient - Diagnostic Centres (Rs/Patient)
    • Number of Daily Patients - Diagnostic Centres (Ths)
    • Number of Samples - Quarterly (Million)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Dr. Lal Pathlabs Ltd. Business

    Dr. Lal Pathlabs Limited is a leading provider of diagnostic and related healthcare tests and services in India, offering a comprehensive range of services to individual patients, hospitals, healthcare providers, and corporate customers.

    Dr. Lal Pathlabs major competitors are Vijaya Diagnostic, Metropolis Health., Thyrocare Tech., Vimta Labs, Krsnaa Diagnostics, Nidan Labs. & Health, Medplus Health Servi.
    Market Cap of Dr. Lal Pathlabs is ₹27,415 Crs.
    While the median market cap of its peers are ₹6,321 Crs.

    Dr. Lal Pathlabs seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jul Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Dec
    Investor Presentation Apr Jul Mar Jun Sep Dec Mar Jun Aug Sep Dec Feb Mar May Jun Jul Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Dec
    Conference Call Mar Aug Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material